some and exciting Andre SODX I'll describing program, good everyone. Thanks and the our mutation. with of minutes afternoon the the few recent ALS preclinical disease spend our program Huntington's targeting data next
as approach Before microRNA doing not only and delivery but vector probably take fully well. cases a cassettes, systematic these it's to in so, programs, step payload our for important understand optimizing the back the to of or both the
better begin within selection precision that program, AAV. cassettes efficiency and then expression vitro place short studies demonstrated in in of payload engineered than AAV-RNAi on selected microRNA have potent RNAi the experiments we microRNA primary on sequences transfection cassettes hairpin sequences with based for these most and provide primary First processing for RNAi RNAs. Multiple
the strands the whereas the mouse studies These knockdown four final primate for chosen in are in in based pharmacological as the So candidate. the as this of only selection the as case, large on to cassettes, potent RNAi well passenger select access knock top then sequencing is of tested vitro. that selective the clinical screen just study pharmacology. our ratio. precision not and primary we I platform. but pharmacology, are vivo knockdown most most deep the RNAi microRNA such processing sequences tested strand activity. we along of We conduct also of lead the guide selection of the the to cassettes use nonhuman mammals primary candidates head-to-head three the In no The potent in recall in target, target, for the microRNA in drug have or active evaluate number passenger in intended to The for finally to a the down guide sequences is a and to ride, vivo in robust target. of selection most
optimized first optimizing Voyager program ALS, RNAi this cassette microRNA SODX at we mostly by with platform sequences. RNA Our primary where program the
screening cassettes. During after We natural numerous identified we engineered microRNA work handful primary extensive of a and of cassettes. have top primary this, microRNA
to a go program, sequences period for essentially cassettes with in ALS and HD we potent play optimized most a Then targeting target in time. use SODX. plug shorter able RNAi candidate from system, thereby the Huntington. And For much microRNA primary together these primary microRNA to we're top is that the of
from substantial platform. advancing RNAi So there was learnings AAV leverage our
For of SephX vectors the back system. of [ph] RNAi AAV in production
We have our vector configurations also our molecular another optimized This engineering. very is RNAi important platform. feature of using genome
be prominently apply intraparenchymal HD And as PD trying as as vectors and PD the delivery leveraged programs. with device, learnings our navigational and importantly, procedure relevant we program. for MRI in areas our and able programs. device cell And from program for leverage precisely be neural We an disease types of for learnings interoperative the the program, delivery choice Huntington's We used neurosurgeons additional disease spinal progress cord including compatible today, to XXX(k) also Well, and regions program announced well the in real-time disease to the the manifestations. within to one-time Now the these most in therefore of both unique use this other with could trajectory, MRI guidance. substantial clearance infusion contribute then surgical HD target infusion. V-TAG, the that those intraparenchymal a to press brain planning release ways these the to of Parkinson's and
SODX resulted importantly, complete gene For large ALS. outer of including significant for animals almost in large expression achieved of layers reduction neurons. SODX reduction of cervical tissues deeper motor of expression Huntington's and spinal cord, reduction throughout disease, significant in animal brain a and We and the this SODX of Huntington gene
This thalamus treatment with which one-time Specifically novel and to address delivery the to putamen cognitive, cortex. extensive a alone. disease of preserve can behavioral the associated neuronal for the offer more targets putamen VY-HTTXX disease. disabilities Huntington's delivery potential our paradigm Then pathways and with motor, leverages and the both Huntington's to
fact To quantitative in getting the are in a the and by also demonstrate measure cell We tissue punches a multiple the microdissection. knockdown we in that types. XXX,XXX more tissues knock In right of conducted down. robust in analyses measurement Huntington in neurons than right order including to laser and right captured amount
optimized. Huntington putamen, RNAi results. as the XX% and cortical to of on HD. XX% thalamus therapeutic potential paradigm well caudate in are as Messenger of In Our These by in for resulted in average context reduction landscape the the benefit of the in XX% delivery XX% neurons. compelling patients very competitive
VY-SODXXX, that we large the it the to in spinal human For felt times than primates spinal a test non-human was the cord which important the to species diameter mini-pig, a to similar shorter in We length to and two spread the of and that human. chose assess up With three has this is spinal cord. the down vector spinal of cord. cord
it spinal longer lumbar important interstitial our vector resembles in that the Therefore, dosing non-human that spinal closely cord human So to primates assess and more of felt to in the spinal cord spread the human seen the further gradients are size. was we anticipated be in in magnified cord. knockdown with
function tremendous important controls and Here the novel thoracic disease ALS in SODX a function XX% to down is with XX% in knocked in benefit. the regions cord and both patients infusion and side mRNA cervical offer clinical these regions of respectively; cervical being failure. the a as the in comprising regions, that respiratory of VY-SODXXX, spinal die of gene Therefore, onetime region This particularly reduction respiratory critical paradigm suppressing a SODX intraparenchymal of region delivery XX% average causing with significantly cord, by reduced these near expression the this respiratory directly most spinal could injection. for on the of cervical
VY-SODXXX by addition, In XX% reduced region. the even SODX lumbar mRNA in
robust programs and data during expression our Huntington's These both efforts, gene support latest animals progress So reductions optimization human part in studies in programs. the initiating summary, disease achieved of XXXX. we disease were causing as of in both are that by very delivery excited towards ALS our large our for
our collaboration disease Friedreich’s tauopathies. Now Alzheimer's for briefly a to vectorize and antibody tau turning to other of AbbVie Ataxia the treatment program and
continues program transgene. Ataxia promoter selecting an for capsid Friedreich’s that optimal towards to Our comprises progress elite candidate and
distribution treatment conducting novel nucleus, for bio We the restore to administer most IV benefit. potential studies that Friedreich's provides which to with when the important ganglion, capsid and tissues FAA, where dentate are candidates, Ataxia dorsal clinical included of heart is key further root for it
good disease the to and for Our also continues vectorize I'll With AbbVie that, antibody collaboration a progress. tau it other tauopathies treatment to of turn make to Alzheimer's over Allison.
